Latest Healthcare News

Pharmx Technologies has entered a multi-year strategic alliance with Sigma Healthcare, becoming the preferred EDI provider for Sigma and Chemist Warehouse across Australia and New Zealand, while Sigma takes a significant equity stake.

Biome Australia Limited has reported a robust half-year performance, with revenues climbing nearly 40% and net profit more than doubling, driven by strong product momentum and strategic investments.

Fisher & Paykel Healthcare has raised its full-year revenue and profit forecasts for FY26, buoyed by strong hospital product growth and favourable exchange rates, while navigating the complexities of a recent US Supreme Court tariff ruling.

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

PolyNovo Limited reported a robust 25.2% increase in half-year revenue to A$75 million, driven by strong U.S. sales and product growth, despite a near break-even net profit impacted by a manufacturing slowdown and a fire at its R&D lab.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Ramsay Health Care is set to simplify its corporate structure by distributing its majority stake in European healthcare provider Ramsay Santé directly to shareholders, enabling focused growth strategies for both entities.

BTC Health reports a slight statutory loss in HY26 amid a 7% revenue dip, offset by strong growth in its cardio segment driven by key hospital contracts.

Cyclopharm Limited is rapidly scaling its US presence for Technegas®, securing new contracts across federal institutions and major health networks in four key regions. The company aims for up to 300 installations by late 2026, boosting recurring revenue streams.

Alcidion has secured regulatory approval for its AI-powered clinical tool in Australia and the UK, paving the way for commercial rollout in its largest markets. This milestone strengthens its position in healthcare technology and opens new sales avenues.

BPH Global is nearing completion of its novel seaweed-based men’s health supplement, Project Popeye, as it moves toward TGA listing and scientific validation.